ArticleBiomaterials2016
A targeted nanoglobular contrast agent from host-guest self-assembly for MR cancer molecular imaging.
Article in Biomaterials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 60 citations in OpenAlex.
- Convergent Evolution: Self-Assembly of Small Molecule, Polymeric, and Inorganic Contrast Agents toward Advanced MRI.Journal of the American Chemical Society · 2025Review
- The Application of Nanomaterials in Breast Cancer.Pharmaceutics · 2025Review
- POSS Engineering of Multifunctional Nanoplatforms for Chemo-Mild Photothermal Synergistic Therapy.International journal of molecular sciences · 2024Article
- Lysosomal Targeting of β-Cyclodextrin.Chemistry (Weinheim an der Bergstrasse, Germany) · 2023Article
- Cyclodextrins: promising scaffolds for MRI contrast agents.RSC advances · 2021Review
- Design of Cyclodextrin-Based Functional Systems for Biomedical Applications.Frontiers in chemistry · 2021Review
- Cyclodextrin-Based Contrast Agents for Medical Imaging.Molecules (Basel, Switzerland) · 2020Review
- Molecular conjugation using non-covalent click chemistry.Nature reviews. Chemistry · 2019Article
- Synthesis and In Vitro Study of a Dual-Mode Probe Targeting Integrin αNanoscale research letters · 2018Article
- Targeted gadofullerene for sensitive magnetic resonance imaging and risk-stratification of breast cancer.Nature communications · 2017Article
- Dual Contrast - Magnetic Resonance Fingerprinting (DC-MRF): A Platform for Simultaneous Quantification of Multiple MRI Contrast Agents.Scientific reports · 2017Article
- Lipid Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung Cancer.Pharmaceutical research · 2017Article
- Gastrin-releasing peptide receptor-targeted gadolinium oxide-based multifunctional nanoparticles for dual magnetic resonance/fluorescent molecular imaging of prostate cancer.International journal of nanomedicine · 2017Article
- Visualization of Fluoride Ions In Vivo Using a Gadolinium(III)-Coumarin Complex-Based Fluorescence/MRI Dual-Modal Probe.Sensors (Basel, Switzerland) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
The clinical application of nanoparticular Gd(III) based contrast agents for tumor molecular MRI has been hindered by safety concerns associated with prolonged tissue retention, although they can produce strong tumor enhancement. In this study, a targeted well-defined cyclodextrin-based nanoglobular contrast agent was developed through self-assembly driven by host-guest interactions for safe and effective cancer molecular MRI. Multiple β-cyclodextrins attached POSS (polyhedral oligomeric silsesquioxane) nanoglobule was used as host molecule. Adamantane-modified macrocyclic Gd(III) contrast agent, cRGD (cyclic RGDfK peptide) targeting ligand and fluorescent probe was used as guest molecules. The targeted host-guest nanoglobular contrast agent cRGD-POSS-βCD-(DOTA-Gd) specifically bond to αvβ3 integrin in malignant 4T1 breast tumor and provided greater contrast enhancement than the corresponding non-targeted agent. The agent also provided significant fluorescence signal in tumor tissue. The histological analysis of the tumor tissue confirmed its specific and effective targeting to αvβ3 integrin. The targeted imaging agent has a potential for specific cancer molecular MR and fluorescent imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.